RecruitingPhase 4ACTRN12611000571976
Efficacy of Highly Selective-a-1A-Adrenoceptor Antagonist Silodosin in Expulsive Therapy of Lower Ureteral Stones: A Randomized Controlled Study
Efficacy of highly selective-a-1A-adrenoceptor antagonist in expulsive therapy of lower ureteral stones
Sponsor
Chung Jing Wang
Enrollment
45 participants
Start Date
Oct 1, 2010
Study Type
Interventional
Conditions
Summary
a comparative study to evaluate the clinical role of highly selective a-1A blocker in the medical expulsive therapy of symptomatic lower ureteral stones.
Eligibility
Sex: Both males and femalesMin Age: 20 YearssMax Age: 60 Yearss
Inclusion Criteria1
- symptomatic radiopaque lower ureteral stones >5mm aged between 20 and 60 years old
Exclusion Criteria1
- Subjects with urinary tract infections, high-grade hydronephrosis, diabetes, ulcers, or a history of hypersensitivity toa-1 blocker and pregnant women were excluded. Patients with a history of spontaneous stone expulsion, hypotension, or those found to have systolic blood pressure lower than 110 mmHg were also excluded.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
orally highly selective a-1A blocker(silodosin 4 mg and tamsulosin 0.2 mg) once daily for 2 weeks
orally highly selective a-1A blocker(silodosin 4 mg and tamsulosin 0.2 mg) once daily for 2 weeks
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000571976